Cytokinetics Reports First Full Quarterly Sales for MYQORZO as Armistice Capital Increases Stake

Biopharmaceutical firm Cytokinetics announced its first complete quarter of sales for its drug MYQORZO, while hedge fund Armistice Capital expanded its ownership position during the same period. The developments highlight growing institutional interest despite broader market pressures in the biotech sector.

28 Aug, 17:29 — 28 Aug, 17:29

Post Share

Sources

Showing 1 of 1 sources

punch-ngMostly Factual14h ago

Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise its stake in the company, at a time when several biopharma-focused hedge funds were absorbing losses on concentrated bets elsewhere in the industry. MYQORZO’s First Full Quarter Cytokinetics reported $25.3 million in net product Read More: https://punchng.com/cytokinetics-posts-first-full-myqorzo-quarter-as-armistice-capital-adds-to-its-position/

By Punch Newspapers

Read full article →

PERSPECTA

PERSPECTA

Cytokinetics Reports First Full Quarterly Sales for MYQORZO as Armistice Capital Increases Stake

Sources

Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Related Stories

OpenAI Terminates Partnership With SpaceX-Backed AI Tool Cursor

NASA to launch $4.3bn Roman space telescope to study dark matter and exoplanets

Widow Files Lawsuit Against Singapore Airlines Over Turbulence Fatality

Nepal flood damage could cost up to a tenth of economy to rebuild

PERSPECTA